News | December 18, 2025
Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Subscribe To Our Newsletter & Stay Updated
